CRA is a proud sponsor of the event covering divisional patent strategies, denigration, Article 102, enforcement, mergers, distribution, as well as implications of the current geopolitical landscape for the pharma sector.
Elina Koustoumpardi is a speaker during the session titled “Merger Control in Non-Horizontal Transactions” discussing:
- Merger control in non-horizontal transactions: lessons learnt from Novo Holdings/Novo Nordisk/Catalent transaction
- Novo Nordisk/Catalent: takeaways for vertical pharma deals involving upstream input suppliers, including analysis of capacity constraints in markets with captive and merchant production, and analysis of potential harm to innovation and potential entry
- Interplay between merger control and regulatory considerations in supply chain transactions: transactions involving products in shortages and critical medicines
- Other non-horizontal considerations, including scope for merger control review of potential harm to non-competitors
For more information on this event, click here.
